Data on maternal-fetal transmission and safety of antiretroviral treatment during pregnancy. Almost everywhere in the world, drugs included in the first treatment lines are a combination of two nucleoside reverse transcriptase inhibitors (lamivudine [3TC] or emtricitabine [FTC] plus tenofovir [TDF], mainly), together with a third drug that in most cases is a non-nucleoside reverse transcriptase inhibitor (especially nevirapine or efavirenz). Efavirenz (EFV) is a very safe and effective drug, whose main toxicity relates to the central nervous system (dizziness and insomnia during the first weeks of treatment). In animal experimental studies, the use of EFV is associated with the development of congenital defects [2]. However, these data have not been confirmed in registries of women with HIV who continued taking this drug during pregnancy. In general, EFV is the most widely used drug in pregnant women but data of potential toxicity make it reasonable to look for better tolerated regimes. In this IAS congress the results of the Tsepamo [3] study have been presented; this is a prospective observational study carried out in Botswana which included 5,438 pregnant women, and which analyzed the risks of toxicity associated with the use of EFV / FTC / TDF and dolutegravir (DTG) together with FTC/TDF. In the study the complications related to treatment were low, quite similar to those observed in general population (around 10% of pregnancies) and there were no differences between both types of treatment in adverse effects during pregnancy (adjusted relative risk [aRR] 1.0 (95% CI 0.9-1.1), neonatal death (aRR 0.9 IC95% 0.6-1.5), prematurity (aRR 1.0, IC95% 0.8-1.1) or low birth weight (aRR 1.0 IC95% 0.9-1.2). These results suggest that EFV neonatal toxicity is very low, which reinforces that it is a safe drug in these circumstances. DTG, however, has the same low toxicity and is well tolerated in this situation, so it can be considered an alternative drug to the EFV, when circumstances do not allow for it to be used.

New antiretroviral drugs. Bictegravir (BIC) is a new integrase inhibitor that has been studied in combination with
tенофовир аляфена́мид (TAF) и FTC, in a single pill. It has the advantage of having a high genetic barrier to resistance. Its favorable pharmacokinetics allows once a day administration, and it does not require an enhancer. In this congress the results of two trials comparing BIC / TAF / FTC to DTG, which is the most modern inhibitor of integrase with very similar characteristics to BIC, have been presented. The GS-US1489 [4] trial is a double-blind study comparing BIC / TAF / FTC against DTG / abacavir (ABC) / 3TC in 630 naive patients; after 48 weeks of treatment there were no significant differences in the patients with undetectable viral load (<50 copies). The double-blind trial GS-US 1490 [5], (BIC / TAF / FTC compared to DTG plus TAF / FTC in 640 naive patients) confirmed that there were no significant differences between both arms. In both studies, the viral response rates were higher than 90% of the patients, and no viral failures or resistance mutations were detected. In the protocol analysis, more than 99% of the patients presented viral suppression at week 48 (figure 1). These magnificent results of BIC / TAF / FTC combination anticipate a very promising future for this treatment.

Darunavir/cobicistat/TAF/FTC. Darunavir (DRV) is a protease inhibitor (PI) that has been combined in a single pill along with cobicistat (COBI), TAF and FTC. Clinical trials results about this switching strategy with very good results were published. The Emerald study [6] is an open-label study that included 11,459 patients on PI treatment, who were randomized to continue with the same regimen or switch to DRV/COBI/ TAF/FTC in a single pill. At 48 weeks, 95% of patients had viral suppression <50 copies, with no differences between the two arms; virological failures were below 1% with no differences between the two arms of the study and resistance mutations were not detected. In the TAF arm, patients developed an improvement in bone mineral density and a reduction in tubular toxicity markers compared to patients in the control arm. This new unique tablet composed of protease inhibitors has very positive levels of efficacy and safety.

Long-acting therapies cabotegravir/rilpivirine (CBG/RPV). Long-term treatments offer advantages over oral treatment that may be relevant for some patients. The most important is the improvement in compliance, since an intramuscular dose (IM) applied every 2 months could cover the whole treatment during this period. CBG/RPV is a drug combination administered parenterally that has been studied for a short time offering promising results. In the Latte-2 study [7], two doses of CBG / RPV were compared by IM route (every month and every 2 months) versus CBG + ABC / 3TC orally. In IAS 2017, the data for week 96 were published, showing the non-inferiority of both parental branches, compared to the VO; specifically, 87% of those assigned to CBG / RPV IM each month had HIV-1 RNA < 50 copies /ml in week 96, compared to 94% of those treated with CBG / RPV IM every 2 months and 84% of those treated with CBG + ABC / 3TC orally. 30% of the patients who received IM treatment had adverse effects related to the injection, mostly mild. 88% of the patients assigned to IM treatments were very satisfied with this medication compared to 43% of those who received oral treatment. The results of the phase III trials are expected because these therapeutic strategies can be very interesting for many patients.

Figura 1 New antiretroviral drugs. Data from IAS 2017. Bictegravir/TAF/FTC vs Dolutegravir-containing regimens. Adapted from Gallant J et al [4] and Sax PE. et al [5]
Dual therapies (dolutegravir/rilpivirine) as a simplification strategy. Treatments based on two drugs may be useful in some patients as a simplification to diminish drug toxicity. At IAS 2017 the results of the Sword Clinical Trial [8] (combination of dolutegravir and rilpivirine, DTG/RPV) have been published. It included 1,024 patients with HIV infection who had suppressed viral load and who were randomized to receive either DTG/RPV or to continue with their basic treatment. At 48 weeks, 95% of the patients continued to be under viral suppression. Significant improvement in bone mineral density was observed, since 73% of patients received TDF at the time of study inclusion.

REFERENCES

1. Nkambule R, Nuwagaba-Biribonwoha H, Mnisi Z, Ao TT, Ginindza C, Duong YT, et al. Substantial progress in confronting the HIV epidemic in Swaziland: first evidence of national impact. 9th IAS Conference on HIV Science. Paris, 2017. Abstract MOAX0204LB
2. Ford N, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2014;28:S123-31. PMID: 24849471 DOI: 10.1097/QAD.0000000000000231.
3. Zash R, Jacobson D, Mayondi G, Díseko M, Makhema J, Mmalane, et al. Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir / emtricitabine (EFV/TDF/ FTC) in nationwide birth outcomes surveillance in Botswana. 9th IAS Conference on HIV Science. Paris, 2017. Abstract MOAX0202LB
4. Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. A phase randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48. 9th IAS Conference on HIV Science. Paris, 2017. Abstract MOAB0105LB
5. Sax PE, Pozniak A, Arribas J, DeJesus E, Stellbrink HJ, et al. Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + TAF in treatment-naïve HIV-1 positive adults: week 48 results. 9th IAS Conference on HIV Science. Paris, 2017. Abstract TUPDB0201LB
6. Molina JM, Gallant J, Orkin C, Negredo E, Bhatti L, Gathe J, et al. Efficacy and safety of switching from boosted-protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults through 24 weeks: EMERALD study. 9th IAS Conference on HIV Science. Paris, 2017. Abstract TUAB0101
7. Eron J, Margolis D, Gonzalez-Garcia J, Stellbrink HJ, Yazdanpanah Y, Podzamczer D, et al. Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results. 9th IAS Conference on HIV Science. Paris, 2017. Abstract MOAX0205LB.
8. Llibre JM, Hung CC, Brinson C, Castellim F, Girard PM, Kahl L, et al. Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks. Conference on Retroviruses and Opportunistic Infections 2018. Seattle, 2017. Abstract 44LB